Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

NCT02756364 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

141

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Fulvestrant
DRUG: Sapanisertib

Sponsor

Calithera Biosciences, Inc